| Literature DB >> 29692760 |
Christoph Jans1, Annemarie Boleij2.
Abstract
The Streptococcus bovis/Streptococcus equinus complex (SBSEC) comprises several species inhabiting the animal and human gastrointestinal tract (GIT). They match the pathobiont description, are potential zoonotic agents and technological organisms in fermented foods. SBSEC members are associated with multiple diseases in humans and animals including ruminal acidosis, infective endocarditis (IE) and colorectal cancer (CRC). Therefore, this review aims to re-evaluate adhesion and colonization abilities of SBSEC members of animal, human and food origin paired with genomic and functional host-microbe interaction data on their road from colonization to infection. SBSEC seem to be a marginal population during GIT symbiosis that can proliferate as opportunistic pathogens. Risk factors for human colonization are considered living in rural areas and animal-feces contact. Niche adaptation plays a pivotal role where Streptococcus gallolyticus subsp. gallolyticus (SGG) retained the ability to proliferate in various environments. Other SBSEC members have undergone genome reduction and niche-specific gene gain to yield important commensal, pathobiont and technological species. Selective colonization of CRC tissue is suggested for SGG, possibly related to increased adhesion to cancerous cell types featuring enhanced collagen IV accessibility. SGG can colonize, proliferate and may shape the tumor microenvironment to their benefit by tumor promotion upon initial neoplasia development. Bacteria cell surface structures including lipotheichoic acids, capsular polysaccharides and pilus loci (pil1, pil2, and pil3) govern adhesion. Only human blood-derived SGG contain complete pilus loci and other disease-associated surface proteins. Rumen or feces-derived SGG and other SBSEC members lack or harbor mutated pili. Pili also contribute to binding to fibrinogen upon invasion and translocation of cells from the GIT into the blood system, subsequent immune evasion, human contact system activation and collagen-I-binding on damaged heart valves. Only SGG carrying complete pilus loci seem to have highest IE potential in humans with significant links between SGG bacteremia/IE and underlying diseases including CRC. Other SBSEC host-microbe combinations might rely on currently unknown mechanisms. Comparative genome data of blood, commensal and food isolates are limited but required to elucidate the role of pili and other virulence factors, understand pathogenicity mechanisms, host specificity and estimate health risks for animals, humans and food alike.Entities:
Keywords: Streptococcus gallolyticus; Streptococcus infantarius; Streptococcus lutetiensis; colorectal cancer; infective endocarditis; microbiota; pilus; virulence
Year: 2018 PMID: 29692760 PMCID: PMC5902542 DOI: 10.3389/fmicb.2018.00603
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1SBSEC - the road to infection. Graphical overview of the different niches inhabited by SBSEC members as well as relevant aspects of host colonization, adherence, invasion and infection covered in the corresponding chapters indicated by bullet point numbers. 1. Prevalence and colonization of SBSEC in animals and humans, 2. Transmission and niche adaptation of SBSEC members, 3. Mechanisms and virulence factors responsible for adhesion and host colonization by SBSEC members, 4. Invasion and infection establishment, 5. Clinical infections and host-immune response due to SBSEC in animals and humans.
SBSEC prevalence in the GIT in studies including healthy people and patients with gastrointestinal conditions sorted by year of publication.
| USA | Patients selected for CRC, inflammatory bowel disease, non-colonic neoplasms, gastrointestinal disorders. Controls among hospital workers and patients with no apparent gastrointestinal disease | Rectal swabs | Controls | 105 | 11 | n.d. | Selective culturing | Phenotypic identification | Klein et al., |
| CRC patients | 63 | 56 | |||||||
| IBD | 25 | 28 | |||||||
| Non-colonic neoplasma | 21 | 19 | |||||||
| GID | 37 | 14 | |||||||
| UK | Hospital population in- and outpatients | Stool | Adults | 39 | 5 | n.d. | Selective culturing | Phenotypic identification | Noble, |
| Neonates | 21 | 24 | |||||||
| USA | Outpatients undergoing colonoscopy for suspected CRC and polyps | Stool | Stool before colonoscopy | 35 | 3 | n.d. | Selective culturing | Group D streptex | Norfleet and Mitchell, |
| Aspirated colon fluid | Aspirated colon fluid | 40 | 8 | ||||||
| Tissue biopsies | Normal remote | 40 | 0 | ||||||
| Normal adjacent | 40 | 0 | |||||||
| Adenoma | 33 | 3 | |||||||
| Carcinoma | 6 | 0 | |||||||
| UK | CRC cases matched to patients having surgery for benign disease or diagnostic colonoscopy | Stool | Control | 23 | 13 | n.d. | Selective culturing | Phenotypic identification | Potter et al., |
| CRC | 19 | 11 | |||||||
| Tissue samples | Control | 23 | 4 | ||||||
| Normal CRC | 19 | 5.5 | |||||||
| Tumor CRC | 19 | 11 | |||||||
| Blood | Control | 23 | 0 | ||||||
| CRC | 19 | 0 | |||||||
| Malaysia | CRC patients with (bac+) and without bacteremia (bac−) and controls in tumor (TU) and non-tumor (NTU) specimens | Stool | Control | 50 | 12 | 8% | Selective culturing and DNA-based detection* | Phenotypic identification | Abdulamir et al., |
| CRC bac− | 52 | 13 | 10% | ||||||
| CRC bac+ | 39 | 13 | 10% | ||||||
| Mucosal washes | Control | 50 | 6 | 4% | |||||
| CRC bac− (TU) | 52 | 10 | 8% | ||||||
| CRC bac− (NTU) | 52 | 6 | 4% | ||||||
| CRC bac+ (TU) | 39 | 5 | 5% | ||||||
| CRC bac+ (NTU) | 39 | 5 | 5% | ||||||
| Tissue specimens | Control | 50 | 2 | 2% | |||||
| CRC bac− (TU) | 52 | 17 | 17% (32.7%)* | ||||||
| CRC bac− (NTU) | 52 | 12 | 12% (23.0%)* | ||||||
| CRC bac+ (TU) | 39 | 21 | 21% (48.7%)* | ||||||
| CRC bac+ (NTU) | 39 | 13 | 13% (35.9%)* | ||||||
| Malaysia | Hospital population with CRC, inflammatory bowel disease and chronic gastrointestinal tract diseases (cases) and healthy individuals (controls) | Stool | Controls | 96 | 7 | n.d. | Selective culturing | Not described | Al-Jashamy et al., |
| IBD & chronic GID | 29 | 52 | |||||||
| CRC & adenoma | 41 | 46 | |||||||
| France | Colonoscopy patients. Not selected for disease | Stool | Normal colonoscopy | 134 | 6 | 0.4% | Selective culturing | 16S rRNA gene | Chirouze et al., |
| Non-tumoral lesions | 76 | 1 | 0.7% | ||||||
| Adenoma & carcinoma | 49 | 6 | 3.5% | ||||||
| Brazil | Colonoscopy patients in hospital | Rectal swab | Colonoscopy | 54 | 35 | 11% | Culture-independent | qPCR targeting | Lopes et al., |
| 13% | |||||||||
| 20% | |||||||||
| 11% | |||||||||
| Israel | Colonoscopy patients. Acceptable indications for colonoscopy included screening for colorectal malignancy, postpolypectomy surveillance, and investigation of symptoms including hematochezia, abdominal pain, and change in bowel habits | Stool, aspirated colonic fluid and colonic tissue | Normal colonoscopy | 105 | 12 | n.d. | Selective culturing | VITEK2 | Boltin et al., |
| Non-advanced or advanced lesions | 13 | 15 | n.d. | ||||||
| South Africa | (Cohort 1) Patients with CRC without pre-selecting conditions | Tissue | Adenocarcinoma and adjacent normal | 55 | 0 | Not detected | Culture-independent | Viljoen et al., | |
| (Cohort 2) Patients with sporadic microsatellite instability | Tissue | Adenocarcinoma | 18 | 0 | Not detected | ||||
| Spain | Unselected CRC patients | Matched tissue | Normal mucosa | 190 | 0 | Not detected | Culture-independent | Andres-Franch et al., | |
| Tumor | 190 | 6 | 3% | ||||||
| Germany | General population | Stool | Healthy controls | 99 | 63 | 63% | Culture-independent | qPCR targeting | Dumke et al., |
| Kenya | Colonoscopy patients. Not selected for disease | Rectal swab | Normal colonoscopy | 193 | 14 | 8% | Selective culturing | 16S rRNA gene | Kaindi et al., |
| Adenomas & carcinomas | 80 | 22 | 22% | ||||||
| USA | Tumor and normal adjacent tissue | Tissue | Adjacent normal | 128 | 47 | 47% | Culture-independent | 16S rRNA gene qPCR | Kumar et al., |
| Carcinoma | 148 | 74 | 74% |
bac+, patients with bacteremia; bac−, patients without bacteremia; GID, gastrointestinal disorders; IBD, inflammatory bowel disease; n.d., not determined; NTU, non-tumor tissue specimen; TU, tumor tissue specimen.
Adhesion of SBSEC species to cell lines.
| Bovine rumen epithelial cell line not differentiated | – | – | – | – | 100% (2/2) | Bovine rumen | Keratinization positively influenced adhesion. Adhesion stronger to bovine than ovine cells | Semjén and Gálfi, |
| Bovine rumen epithelial cell line non-keratinized | – | – | – | – | 0% (0/4) | Bovine rumen | Styriak et al., | |
| – | – | – | – | 0% (0/3) | Bovine rumen | Biotype II | Styriak et al., | |
| Bovine rumen epithelial cell line keratinized | – | – | – | – | 100% (4/4) | Bovine rumen | Styriak et al., | |
| – | – | – | – | 100% (3/3) | Bovine rumen | Biotype II | Styriak et al., | |
| Ovine rumen epithelial cell line | – | – | – | – | 100% (2/2) | Bovine rumen | Keratinization positively influenced adhesion. Adhesion stronger to bovine than ovine cells. | Semjén and Gálfi, |
| Ovine rumen epithelial cell line non-keratinized | – | – | – | – | 20% (1/5) | Bovine rumen | Styriak et al., | |
| – | – | – | – | 0% (0/4) | Bovine rumen | Styriak et al., | ||
| Ovine rumen epithelial cell line keratinized | – | – | – | – | 100% (5/5) | Bovine rumen | Styriak et al., | |
| – | – | – | – | 100% (4/4) | Bovine rumen | Styriak et al., | ||
| Oral/primary buccal epithelial cells | 100% (3/3) | – | – | – | 100% (2/2) | Human IE | Von Hunolstein et al., | |
| – | – | – | – | 100% (1/1) | Bovine feces | Von Hunolstein et al., | ||
| Human Caco-2 | 100% (2/2) | – | – | – | – | Bovine feces | Sánchez-Díaz et al., | |
| 100% (2/2) | – | – | – | – | Human blood | Sánchez-Díaz et al., | ||
| 100% (1/1) | – | – | – | – | Human feces | Ellmerich et al., | ||
| – | – | 100% (1/1) | – | – | Human blood | Ellmerich et al., | ||
| 100% (3/3) | – | – | – | – | Human blood | Boleij et al., | ||
| 100% (1/1) | – | – | – | – | Human feces | Boleij et al., | ||
| – | 100% (1/1) | – | – | – | Dairy | Boleij et al., | ||
| – | – | – | 18% (3/17) | – | Sea otter IE | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter feces | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter brain | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter lymph | Counihan et al., | ||
| – | – | – | 100% (1/1) | – | Sea otter ulcer | Counihan et al., | ||
| Human epithelioid carcinoma cell line KB ECACC 86103004 | 100% (1/1) | – | – | – | – | Human feces | Ellmerich et al., | |
| – | – | 100% (1/1) | – | – | Human blood | Ellmerich et al., | ||
| Human HCT116 | 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | |
| Human HT-29 | 100% (3/3) | – | – | – | – | Human blood | Boleij et al., | |
| 100% (1/1) | – | – | – | – | Human feces | Boleij et al., | ||
| – | 100% (1/1) | – | – | – | Dairy | Boleij et al., | ||
| 100% (1/1) | – | – | – | – | Human IE | Martins et al., | ||
| 100% (5/5) | – | – | – | – | Human IE | Kumar et al., | ||
| 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | ||
| Human HT-29 MTX | 100% (1/1) | – | – | – | – | Human IE | higher adhesion to HT-29 MTX vs. HT-29 | Martins et al., |
| Mouse rectum carcinoma CMT-93 | – | – | – | 6% (1/17) | – | Sea otter IE | Counihan et al., | |
| – | – | – | 0% (0/1) | – | Sea otter feces | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter brain | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter lymph | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter ulcer | Counihan et al., | ||
| Human SW1116 | 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | |
| Human SW480 | 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | |
| Human 494 umbilical vein HUVEC | – | – | – | 41% (7/17) | – | Sea otter IE | Counihan et al., | |
| – | – | – | 0% (0/1) | – | Sea otter feces | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter brain | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter lymph | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter ulcer | Counihan et al., | ||
| Mouse endothelial tumor EOMA | – | – | – | 47% (8/17) | – | Sea otter IE | Counihan et al., | |
| – | – | – | 0% (0/1) | – | Sea otter feces | Counihan et al., | ||
| – | – | – | 100% (1/1) | – | Sea otter brain | Counihan et al., | ||
| – | – | – | 0% (0/1) | – | Sea otter lymph | Counihan et al., | ||
| – | – | – | 100% (1/1) | – | Sea otter ulcer | Counihan et al., | ||
| Human unnamed saphenous vein | 100% (1/1) | – | – | – | – | Human feces | Ellmerich et al., | |
| – | – | 100% (1/1) | – | – | Human blood | Ellmerich et al., | ||
| Human vascular endothelial EA.hy926 | 100% (21/21) | – | – | – | – | Human clinical IE/blood/other | Vollmer et al., | |
| 100% (1/1) | – | – | – | – | Koala feces | Vollmer et al., | ||
| 100% (1/1) | – | – | – | – | Shea cake digester | Vollmer et al., | ||
| Human lung carcinoma A549 | 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | |
| Human normal colon epithelial cell line CCD 841 CoN | 100% (2/2) | – | – | – | – | Human IE | Kumar et al., | |
| THP−1 human monocytes | 100% (1/1) | – | – | – | – | Human feces | Ellmerich et al., | |
| – | – | 100% (1/1) | – | – | Human blood | Ellmerich et al., | ||
Adhesion of SBSEC species to different extracellular matrix protein (ECM) types.
| Type I (calf skin) | 0% (0/9) | – | 0% (0/5) | – | – | – | Pigeon streptococcosis | Vanrobaeys et al., |
| Type I (human) | 25% (6/24) | – | – | – | – | – | animal | Grimm et al., |
| 0% (0/1) | – | – | – | – | – | Food | Grimm et al., | |
| 78% (35/45) | – | – | – | – | – | Human blood | Grimm et al., | |
| 0% (0/2) | – | – | – | – | – | Human feces | Grimm et al., | |
| 0% (0/2) | – | – | – | – | – | Unknown | Grimm et al., | |
| Type I (rat tail) | 100% (1/1) | – | – | – | 0% (0/1) | – | Animal | Jans et al., |
| 100% (2/2) | – | – | – | – | – | Bovine feces | Sánchez-Díaz et al., | |
| – | 60% (3/5) | – | 10% (3/29) | – | – | Dairy | Jans et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 75% (3/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| 100% (2/2) | – | – | – | – | – | Human blood | Sánchez-Díaz et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 100% (1/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| 73% (11/15) | – | 100% (1/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| Type I (source n/a) | 100% (23/23) | – | – | – | – | – | Human IE and others | Vollmer et al., |
| 100% (3/3) | – | – | – | – | – | Human IE | Boleij et al., | |
| 100% (1/1) | – | – | – | – | – | Animal feces | Boleij et al., | |
| – | 100% (1/1) | – | – | – | – | Dairy | Boleij et al., | |
| Type II (source n/a) | 96% (22/23) | – | – | – | – | – | Human IE and others | Vollmer et al., |
| Type III (calf skin) | 22% (2/9) | – | 0% (0/5) | – | – | – | Pigeon streptococcosis | Vanrobaeys et al., |
| Type IV (human) | 100% (1/1) | – | – | – | 0% (0/1) | – | animal | Jans et al., |
| 100% (2/2) | – | – | – | – | – | Bovine feces | Sánchez-Díaz et al., | |
| – | 20% (1/5) | – | 14% (4/29) | – | – | Dairy | Jans et al., | |
| 100% (1/1) | – | – | – | – | – | Food | Grimm et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 75% (3/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 0% (0/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| 60% (9/15) | – | 0% (0/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| 38% (9/24) | – | – | – | – | – | Animal | Grimm et al., | |
| 82% (37/45) | – | – | – | – | – | Human blood | Grimm et al., | |
| 100% (2/2) | – | – | – | – | – | Human blood | Sánchez-Díaz et al., | |
| 0% (0/2) | – | – | – | – | – | Human feces | Grimm et al., | |
| 0% (0/2) | – | – | – | – | – | Unknown | Grimm et al., | |
| Type IV (mouse sarcoma) | 89% (8/9) | – | 100% (5/5) | – | – | – | Pigeon streptococcosis | Vanrobaeys et al., |
| Type IV (mouse tumor) | – | – | – | – | 100% (10/10) | – | Sea otter brain | Counihan et al., |
| Type IV (source n/a) | – | – | 100% (1/1) | – | – | – | Human blood | Ellmerich et al., |
| 100% (1/1) | – | – | – | – | – | Human feces | Ellmerich et al., | |
| 96% (22/23) | – | – | – | – | – | Human IE and others | Vollmer et al., | |
| 100% (3/3) | – | – | – | – | – | Human IE | Boleij et al., | |
| 100% (1/1) | – | – | – | – | – | Animal feces | Boleij et al., | |
| – | 100% (1/1) | – | – | – | – | Dairy | Boleij et al., | |
| Type V (human) | 40% (6/15) | – | 0% (0/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., |
| Fibrinogen (human) | 100% (1/1) | – | – | – | 0% (0/1) | – | Animal | Jans et al., |
| – | 40% (2/5) | – | 7% (2/29) | – | – | Dairy | Jans et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 75% (3/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 100% (1/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| 47% (7/15) | – | 100% (1/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., | |
| 78% (18/23) | – | – | – | – | – | Human IE and others | Vollmer et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| Fibronectin (human) | 100% (1/1) | – | – | – | 0% (0/1) | – | Animal | Jans et al., |
| – | – | – | – | – | 20% (2/10) | Bovine rumen | Styriak et al., | |
| – | 60% (3/5) | – | 7% (2/29) | – | – | Dairy | Jans et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 75% (3/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 0% (0/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| 33% (5/15) | – | 100% (1/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| 67% (6/9) | – | 60% (3/5) | – | – | – | Pigeon streptococcosis | Vanrobaeys et al., | |
| – | – | – | – | 100% (10/10) | – | Sea otter brain | Counihan et al., | |
| Fibronectin (porcine) | – | – | – | – | – | 0% (0/10) | Bovine rumen | Styriak et al., |
| Fibronectin (source n/a) | – | – | 100% (1/1) | – | – | – | Human blood | Ellmerich et al., |
| 100% (1/1) | – | – | – | – | – | Human feces | Ellmerich et al., | |
| 30% (7/23) | – | – | – | – | – | Human IE and others | Vollmer et al., | |
| Heparin | – | – | – | – | – | 0% (0/10) | Bovine rumen | Styriak et al., |
| Lactoferrin (bovine) | – | – | – | – | – | 20% (2/10) | Bovine rumen | Styriak et al., |
| Laminin (mouse tumor) | – | – | – | – | 100% (10/10) | – | Sea otter brain | Counihan et al., |
| Laminin (source n/a) | – | – | 100% (1/1) | – | – | – | Human blood | Ellmerich et al., |
| 100% (1/1) | – | – | – | – | – | Human feces | Ellmerich et al., | |
| 70% (16/23) | – | – | – | – | – | Human IE and others | Vollmer et al., | |
| Mucin type II (porcine stomach) | 100% (1/1) | – | – | – | 100% (1/1) | – | Animal | Jans et al., |
| – | 40% (2/5) | – | 17% (5/29) | – | – | Dairy | Jans et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 100% (4/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 0% (0/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| Tenascin | 70% (16/23) | – | – | – | – | – | Human IE and others | Vollmer et al., |
| Vitronectin (human) | – | – | – | – | – | 20% (2/10) | Bovine rumen | Styriak et al., |
| Vitronectin (source n/a) | 22% (5/23) | – | – | – | – | – | Human IE and others | Vollmer et al., |
| Bovine serum albumin (BSA) | 0% (0/1) | – | – | – | 0% (0/1) | – | Animal | Jans et al., |
| – | – | – | – | – | 0% (0/10) | Bovine rumen | Styriak et al., | |
| – | 40% (2/5) | – | 10% (3/29) | – | – | Dairy | Jans et al., | |
| – | – | – | 0% (0/1) | – | – | Food contamination | Jans et al., | |
| – | – | – | 75% (3/4) | 100% (1/1) | – | Human blood | Jans et al., | |
| – | – | 0% (0/1) | – | – | – | Human cerebrospinal fluid | Jans et al., | |
| 0% (0/1) | – | – | – | 0% (0/4) | – | Human feces | Jans et al., | |
| 0% (0/15) | – | 0% (0/1) | – | 0% (0/1) | – | Human IE | Sillanpää et al., | |
| – | – | – | 0% (0/5) | – | – | Human unknown | Jans et al., | |
| – | – | – | – | 100% (10/10) | – | Sea otter brain | Counihan et al., | |
| Human serum albumin (HSA) | – | – | – | – | – | 0% (0/10) | Bovine rumen | Styriak et al., |
23 strains total of which 2 originated from fecal samples of a koala bear (type strain) and one anaerobic shea cake digester isolate, but data was not extractable by strain.
data derived from single strains.
Presence of major known virulence factors of SBSEC members in relation to adhesion, colonization and immune system interaction for SBSEC strains of human, animal and food origin.
| Animal feces | 3 | + (1); − (2) | + (1); − (2) | + (0); − (2); other (1) | + (3); − (0) | + (3); − (0) | + (0); − (1); truncated (1); other (1) | + (3); − (0) | + (3); − (0) | + (3); − (0) | + (2); − (1) | + (3); − (0) | + (0); − (3) | + (0); − (3) | + (3); − (0) | + (0); − (0); other (3) | + (0); − (3) | |
| Animal rumen | 9 | + (3); − (6) | + (3); − (6) | + (0); − (6); other (3) | + (7); − (2) | + (7); − (2) | + (0); − (6); other (3) | + (7); − (2) | + (7); − (2) | + (7); − (2) | + (6); − (3) | + (5); − (4) | + (0); − (9) | + (0); − (9) | + (6); − (3) | + (0); − (4); other (5) | + (0); − (9) | |
| Animal unknown | 8 | + (8); − (0) | + (8); − (0) | + (0); − (0); other (8) | + (7); − (1) | + (7); − (1) | + (0); − (6); other (2) | + (8); − (0) | + (8); − (0) | + (8); − (0) | + (5); − (3) | + (5); − (3) | + (2); − (6) | + (0); − (8) | + (8); − (0) | + (2); − (1); other (5) | + (2); − (6) | |
| Human feces | 2 | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (1); − (1) | + (1); − (1) | + (0); − (1); truncated (1) | + (1); − (1) | + (0); − (1); truncated (1) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (0); − (2) | + (0); − (2) | + (2); − (0) | + (1); − (0); other (1) | + (0); − (2) | |
| Human other | 1 | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (0); − (1) | |
| Unknown | 8 | + (4); − (4) | + (4); − (4) | + (0); − (6); other (2) | + (6); − (2) | + (6); − (2) | + (0); − (5); other (3) | + (8); − (0) | + (8); − (0) | + (8); − (0) | + (7); − (1) | + (6); − (2) | + (0); − (8) | + (0); − (8) | + (7); − (1) | + (3); − (1); other (4) | + (0); − (8) | |
| Animal feces | 2 | + (0); − (2) | + (1); − (1) | + (0); − (1); truncated (1) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (2); − (0) | + (2); − (0) | + (2); − (0) | + (1); − (1) | + (1); − (1) | + (2); − (0) | + (2); − (0) | + (2); − (0) | + (2); − (0) | + (1); − (1) | |
| Animal other | 2 | + (2); − (0) | + (2); − (0) | + (0); − (0); other (2) | + (1); − (0); truncated (1) | + (2); − (0) | + (0); − (0); truncated (1); other (1) | + (2); − (0) | + (2); − (0) | + (2); − (0) | + (0); − (2) | + (0); − (2) | + (0); − (0); other (2) | + (2); − (0) | + (2); − (0) | + (1); − (1) | + (0); − (2) | |
| Animal rumen | 6 | + (3); − (3) | + (6); − (0) | + (0); − (0); other (6) | + (2); − (4) | + (5); − (1) | + (2); − (4) | + (4); − (2) | + (4); − (2) | + (4); − (2) | + (6); − (0) | + (3); − (3) | + (4); − (2) | + (2); − (4) | + (6); − (0) | + (6); − (0) | + (6); − (0) | |
| Human blood | 6 | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (6); − (0) | + (4); − (2) | |
| Human feces | 2 | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (2); − (0) | + (2); − (0) | + (0); − (2) | |
| Food | 2 | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (2); − (0) | + (1); − (0); other (1) | + (0); − (2) | |
| Human blood | 1 | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (0); − (1) | + (1); − (0) | + (1); − (0) | + (0); − (1) | |
| Unknown | 3 | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (0); − (3) | + (1); − (2) | + (1); − (2) | + (0); − (3) | |
| Food | 1 | + (0); − (1) | + (1); − (0) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (1); − (0) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (0); − (0); other (1) | + (0); − (1) | |
| Human feces | 2 | + (0); − (2) | + (1); − (1) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (1); − (1) | + (0); − (2) | + (0); − (2) | + (0); − (2) | + (1); − (1) | + (1); − (1) | + (0); − (2) | |
| Animal other | 1 | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (0); − (1) | + (1); − (0) | + (1); − (0) | + (0); − (1) | |
| Human feces | 1 | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (0); − (1) | + (1); − (0) | + (0); − (0); other (1) | + (0); − (1) | |
| Locus Tag | Gallo_2177 | Gallo _2178 | Gallo _2179 | Gallo _1568 | Gallo _1569 | Gallo _1570 | Gallo _2038 | Gallo _2039 | Gallo _2040 | Gallo _0748 | Gallo _0112 | Gallo _2032 | Gallo _0577 | Gallo _0636 | Gallo _1368 | Gallo _1675 | ||
| Reference protein sequence size (AA) | 275 | 480 | 658 | 275 | 505 | 641 | 312 | 478 | 1664 | 1573 | 1301 | 775 | 750 | 91 | 992 | 759 | ||
| Min. AA sequence match for ≪+≫ | 200 | 400 | 600 | 200 | 400 | 600 | 200 | 400 | 1000 | 1000 | 1000 | 500 | 500 | 50 | 500 | 500 | ||
| Identity threshold (%) | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||
Data derived via a comparative blast search in 60 SBSEC genomes for the presence of virulence genes encoding for pili and adhesion-related proteins based on SGG UCN34 (strain-specific data available in Supplementary Data .
Data derived from blast search using the protein sequences of the nine genes of pil1-3 and further virulence factors of SGG UCN34. A positive hit is indicated by “+” if the AA sequence is above the minimum sequence length determined for each locus and >50% AA sequence identity. “other” indicates AA sequences matching the minimum AA sequence length but <50% AA sequence identity. Genes with high identity but incomplete length are indicated as “truncated.” The numbers in brackets indicate the number of strains for each category in that specific row. Other terminology used for the pilus operons: pil1 as identified by Danne et al. (.
Invasion and translocation ability of SBSEC species in different cell lines.
| Human Caco-2 | 0% (0/3) | – | – | Human blood | Boleij et al., | |
| 0% (0/1) | – | – | Human feces | Boleij et al., | ||
| – | 0% (0/1) | – | Dairy | Boleij et al., | ||
| – | – | 82% (14/17) | Sea otter IE | Only 1 strain with 0.2% invasion, all others low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter feces | Low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter brain | Low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter lymph | Low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter ulcer | Low invasion | Counihan et al., | |
| 0% (0/2) | – | – | Bovine feces | Low invasion | Sánchez-Díaz et al., | |
| 0% (0/2) | – | – | Human blood | Low invasion | Sánchez-Díaz et al., | |
| Human HCT116 | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human HT-29 | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human SW1116 | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human SW480 | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human 494 umbilical vein HUVEC | – | – | 76% (13/17) | Sea otter IE | Low invasion | Counihan et al., |
| – | – | 100% (1/1) | Sea otter feces | Low invasion | Counihan et al., | |
| – | – | 0% (0/1) | Sea otter brain | Low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter lymph | Low invasion | Counihan et al., | |
| – | – | 100% (1/1) | Sea otter ulcer | Low invasion | Counihan et al., | |
| 100% (5/5) | – | – | Human clinical IE/blood/other | Vollmer et al., | ||
| 0% (0/1) | – | – | Koala feces | Vollmer et al., | ||
| Human vascular endothelial EA.hy926 | 100% (21/21) | – | – | Human clinical IE/blood/other | Vollmer et al., | |
| 0% (0/1) | – | – | Koala feces | Vollmer et al., | ||
| 100% (1/1) | – | – | Shea cake digester | Vollmer et al., | ||
| Human lung carcinoma A549 | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human normal colon epithelial cell line CCD 841 CoN | 0% (0/2) | – | – | Human IE | Kumar et al., | |
| Human Caco-2 epithelial monolayer | 50% (1/2) | – | – | Bovine feces | Sánchez-Díaz et al., | |
| 100% (2/2) | – | – | Human blood | Sánchez-Díaz et al., | ||
| 100% (3/3) | – | – | Human blood | Boleij et al., | ||
| 100% (1/1) | – | – | Human feces | Boleij et al., | ||
| – | 0% (0/1) | – | Dairy | Boleij et al., | ||
Association of SBSEC subspecies clinical infections (bacteremia and IE) with underlying colon pathology.
| 28 | 21 | 14 | 6 | 99 | 31 | 257 | 6 | ||||||||||||||
| adenomas | 13 | 46.4 | 5 | 23.8 | 3 | 21.4 | – | – | – | – | 52 | 52.5 | 5 | 16.1 | 103 | 40.1 | 1 | 16.7 | 182 | 39.4 | |
| carcinomas | 1 | 3.6 | 2 | 9.5 | 1 | 7.1 | – | – | – | – | 18 | 18.2 | 5 | 16.1 | 25 | 9.7 | 2 | 33.3 | 54 | 11.7 | |
| neoplasia | 14 | 50.0 | 7 | 33.3 | 4 | 28.6 | – | – | 3 | 50.0 | 70 | 70.7 | 10 | 32.3 | 128 | 49.8 | 3 | 50.0 | 239 | 51.7 | |
| 11 | 24 | 13 | 126 | 26 | |||||||||||||||||
| adenomas | – | – | 0 | 0.0 | 11 | 45.8 | – | – | – | – | – | – | 8 | 6.3 | – | – | 3 | 11.5 | 22 | 11.0 | |
| carcinomas | – | – | 0 | 0.0 | 0 | 0.0 | – | – | – | – | – | – | 19 | 15.1 | – | – | 4 | 15.4 | 23 | 11.5 | |
| neoplasia | – | – | 0 | 0.0 | 11 | 45.8 | – | – | 4 | 30.8 | – | – | 27 | 21.4 | – | – | 7 | 26.9 | 49 | 24.5 | |
| 14 | 5 | 4 | 4 | 6 | |||||||||||||||||
| adenomas | – | – | 3 | 21.4 | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | 2 | 33.3 | 5 | 15.2 | |
| carcinomas | – | – | 1 | 7.1 | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | 0 | 0.0 | 1 | 3.0 | |
| neoplasia | – | – | 4 | 28.6 | 0 | 0.0 | – | – | 2 | 50.0 | – | – | 0 | 0.0 | – | – | 2 | 33.3 | 8 | 24.2 | |
| 2 | 1 | 11 | |||||||||||||||||||
| adenomas | – | – | – | – | 1 | 50.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | – | – | 1 | 7.1 | |
| carcinomas | – | – | – | – | 0 | 0.0 | – | – | – | – | – | – | 0 | 0.0 | – | – | – | – | 0 | 0.0 | |
| neoplasia | – | – | – | – | 1 | 50.0 | – | – | 1 | 100.0 | – | – | 0 | 0.0 | – | – | – | – | 2 | 14.3 | |
| 2 | |||||||||||||||||||||
| adenomas | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2 | 100.0 | 2 | 100.0 | |
| carcinomas | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0 | 0.0 | 0 | 0.0 | |
| neoplasia | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2 | 100.0 | 2 | 100.0 | |
| All SBSEC | |||||||||||||||||||||
| cases | |||||||||||||||||||||
| adenomas | 13 | 43.3 | 8 | 17.4 | 15 | 33.3 | 9 | 24.3 | 0 | 0.0 | 58 | 43.0 | 13 | 7.6 | 103 | 40.1 | 8 | 20.0 | 227 | 28.9 | |
| carcinomas | 1 | 3.3 | 3 | 6.5 | 1 | 2.2 | 3 | 8.1 | 0 | 0.0 | 20 | 14.8 | 24 | 14.0 | 25 | 9.7 | 6 | 15.0 | 83 | 10.6 | |
| neoplasia | 14 | 46.7 | 11 | 23.9 | 16 | 35.6 | 12 | 32.4 | 10 | 41.7 | 78 | 57.8 | 37 | 21.5 | 128 | 49.8 | 14 | 35.0 | 320 | 40.7 | |
All cases associated with neoplasia were S. bovis biotype I (listed under SGG), 2 SB cases had SB biotype II. Bold numbers represent total number of SBSEC cases per study (in columns) or total number of SBSEC cases per subspecies (in lines).
Studies with identification of SB subspecies.
21 of 37 did not undergo colonoscopy, of 14 that underwent colonoscopy at index 7 had adenomas and 3 a carcinoma.
.
Untyped SBSEC cases are only included under “all SBSEC cases” and the total SBSEC species might thus not be equal to the sum of individual species cases.